Animal models for dengue vaccine development and testing

다국어 초록 (Multilingual Abstract)

Dengue fever is a tropical endemic disease; however, because of climate change, it may become a problem in South Korea in the near future. Research on vaccines for dengue fever and outbreak preparedness are currently insufficient. In addition, because there are no appropriate animal models, controversial results from vaccine efficacy assessments and clinical trials have been reported. Therefore, to study the mechanism of dengue fever and test the immunogenicity of vaccines, an appropriate animal model is urgently needed. In addition to mouse models, more suitable models using animals that can be humanized will need to be constructed. In this report, we look at the current status of model animal construction and discuss which models require further development.

참고문헌 (Reference)

1 Robinson JS., "Yucatan miniature swine as an animal model for dengue-1 disease"

2 Zust R, "Type I interferon signals in macrophages and dendritic cells control dengue virus infection: implications for a new mouse model to test dengue vaccines" 88 : 7276-7285, 2014

3 Miller JL, "The mannose receptor mediates dengue virus infection of macrophages" 4 : e17-, 2008

4 Lee SH, "The effects of climate change and globalization on mosquito vectors: evidence from Jeju Island, South Korea on the potential for Asian tiger mosquito (Aedes albopictus) influxes and survival from Vietnam rather than Japan" 8 : e68512-, 2013

5 Wilder-Smith A, "The 2012 dengue outbreak in Madeira: exploring the origins" 19 : 20718-, 2014

6 Halstead SB, "Studies on the pathogenesis of dengue infection in monkeys. II. Clinical laboratory responses to heterologous infection" 128 : 15-22, 1973

7 Halstead SB, "Studies on the pathogenesis of dengue infection in monkeys. I. Clinical laboratory responses to primary infection" 128 : 7-14, 1973

8 Marchette NJ, "Studies on the pathogenesis of dengue infection in monkeys. 3. Sequential distribution of virus in primary and heterologous infections" 128 : 23-30, 1973

9 Perry ST, "STAT2 mediates innate immunity to Dengue virus in the absence of STAT1 via the type I interferon receptor" 7 : e1001297-, 2011

10 Cassetti MC, "Report of an NIAID workshop on dengue animal models" 28 : 4229-4234, 2010

11 GlobalData., "OpportunityAnalyzer: dengue vaccines: opportunity analysis and forecasts to 2020"

12 Goncalvez AP, "Monoclonal antibody-mediated enhancement of dengue virus infection in vitro and in vivo and strategies for prevention" 104 : 9422-9427, 2007

13 Chen J, "Molecular profiling of T-helper immune genes during dengue virus infection" 5 : 165-, 2008

14 Bente DA, "Models of dengue virus infection" 3 : 97-103, 2006

15 Sridharan A, "Inhibition of megakaryocyte development in the bone marrow underlies dengue virus-induced thrombocytopenia in humanized mice" 87 : 11648-11658, 2013

16 St John AL., "Influence of mast cells on dengue protective immunity and immune pathology" 9 : e1003783-, 2013

17 Velandia-Romero ML, "In vitro infection with dengue virus induces changes in the structure and function of the mouse brain endothelium" 11 : e0157786-, 2016

18 Richter MK, "Immature dengue virus is infectious in human immature dendritic cells via interaction with the receptor molecule DC-SIGN" 9 : e98785-, 2014

19 Mota J, "Humanized mice show clinical signs of dengue fever according to infecting virus genotype" 83 : 8638-8645, 2009

20 Liang H, "Guiding dengue vaccine development using knowledge gained from the success of the yellow fever vaccine" 13 : 36-46, 2016

21 Wege AK, "Functional and phenotypic characterization of the humanized BLT mouse model" 324 : 149-165, 2008

22 Murray NE, "Epidemiology of dengue: past, present and future prospects" 5 : 299-309, 2013

23 Villar L, "Efficacy of a tetravalent dengue vaccine in children in Latin America" 372 : 113-123, 2015

24 Guy B, "Development of the Sanofi Pasteur tetravalent dengue vaccine: one more step forward" 33 : 7100-7111, 2015

25 Onlamoon N, "Dengue virus-induced hemorrhage in a nonhuman primate model" 115 : 1823-1834, 2010

26 Yung CF, "Dengue serotype-specific differences in clinical manifestation, laboratory parameters and risk of severe disease in adults, Singapore" 92 : 999-1005, 2015

27 Bente DA, "Dengue fever in humanized NOD/SCID mice" 79 : 13797-13799, 2005

28 Singhi S, "Dengue and dengue hemorrhagic fever: management issues in an intensive care unit" 83 (83): S22-S35, 2007

29 Guzman MG, "Dengue" 385 : 453-465, 2015

30 Tassaneetrithep B, "DC-SIGN (CD209) mediates dengue virus infection of human dendritic cells" 197 : 823-829, 2003

31 Shresta S, "Critical roles for both STAT1-dependent and STAT1-independent pathways in the control of primary dengue virus infection in mice" 175 : 3946-3954, 2005

32 Capeding MR, "Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial" 384 : 1358-1365, 2014

33 Huang CY, "Chimeric dengue type 2 (vaccine strain PDK-53)/dengue type 1 virus as a potential candidate dengue type 1 virus vaccine" 74 : 3020-3028, 2000

34 Ferguson NM, "Benefits and risks of the Sanofi-Pasteur dengue vaccine: Modeling optimal deployment" 353 : 1033-1036, 2016

35 Kutsuna S, "Autochthonous dengue fever, Tokyo, Japan, 2014" 21 : 517-520, 2015

36 Qu X, "Association of Dectin-1 and DC-SIGN gene single nucleotide polymorphisms with fungal keratitis in the northern Han Chinese population" 21 : 391-402, 2015